ACH

Business Context and Reporting Period

Company: Owens & Minor, Inc. (Note: Input metadata referenced "Accendra Health Inc," but the filing text is for Owens & Minor, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2009
Business Overview: A Fortune 500 company and leading national distributor of medical and surgical supplies to the acute-care market. The company provides distribution and supply chain management services to approximately 4,600 healthcare providers from 51 distribution centers. Over 95% of revenue is derived from the distribution of consumable medical and surgical goods.

Key Financial Metrics (Year Ended Dec 31, 2009)

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 11.0% to $8.0 billion. Growth was driven by net new and acquired business (approx. $715 million, primarily from The Burrows Company acquisition) and a 6% increase in sales to existing customers.
• Profitability: Income from continuing operations rose 15.4% to $116.9 million. Operating earnings increased 11.4% to $201.3 million.
• Discontinued Operations: The company exited its direct-to-consumer (DTC) distribution business in January 2009. This resulted in a loss from discontinued operations of $12.2 million in 2009 (compared to $7.9 million in 2008), primarily due to exit costs, partially offset by a $3.2 million gain on the sale of assets.
• Liquidity Improvement: Cash and cash equivalents surged from $7.9 million to $96.1 million. This was driven by strong operating cash flow ($165.3 million) and proceeds from the DTC business sale ($63.0 million), which were used to reduce the revolving credit facility by $150.6 million.
• Debt Reduction: Long-term debt decreased significantly from $359.2 million to $208.4 million as the company paid down borrowings used to fund the 2008 Burrows acquisition.

Guidance, Outlook, Risks, and Unusual Items

• Strategic Initiatives: Management is focusing on profitability improvement through resource management outsourcing (OMSolutions), private label products (MediChoice), and third-party logistics (OM Healthcare Logistics). Capital expenditures of $32.3 million were invested in automation and IT to support these initiatives.
• Dividends: The Board approved a 15% increase in the quarterly dividend to $0.265 per share in February 2010. A three-for-two stock split was also announced.
• Risks:
  • Customer Concentration: Approximately 70% of revenue comes from members of three Group Purchasing Organizations (GPOs): Novation (37%), Premier (20%), and Broadlane (12%).
  • Supplier Concentration: The top ten suppliers accounted for 54% of revenue. Covidien alone represented 14% of revenue.
  • Regulatory Environment: Pending healthcare reform legislation could fundamentally change delivery and payment systems, potentially affecting customer purchasing behavior.
  • Competition: The industry faces intense pricing pressure from competitors like Cardinal Health and Medline.
• Unusual Items: The 2008 results included a $3.1 million loss on the termination of interest rate swaps. The 2009 effective tax rate (37.9%) was lower than 2008 (38.5%) due to tax benefits from the conclusion of IRS audits.

Investor Verification Checklist

• Customer Concentration Risk: Verify the stability of contracts with Novation, Premier, and Broadlane, which collectively represent 69% of revenue.
• Supplier Dependence: Assess the risk of margin compression if major suppliers (e.g., Covidien, J&J) alter terms or bypass distributors.
• Discontinued Operations: Confirm that all exit costs related to the DTC business have been fully recognized and no further liabilities remain.
• Debt Covenants: Review the terms of the $306 million revolving credit facility (expiring May 2011) and the $200 million Senior Notes (due 2016) to ensure compliance with leverage and fixed charge coverage ratios.
• Stock Split Impact: Verify the pro forma impact of the announced three-for-two stock split on share count and per-share metrics for future reporting periods.